Renal tubular dysfunction associated with tenofovir therapy -: Report of 7 cases

被引:211
作者
Peyrière, H
Reynes, J [1 ]
Rouanet, I
Daniel, N
de Boever, CM
Mauboussin, JM
Leray, H
Moachon, L
Vincent, D
Salmon-Céron, D
机构
[1] CHU Montpellier, Guide Chauliac Hosp, Dept Infect Dis, F-34295 Montpellier, France
[2] CHU Montpellier, Lapeyronie Hosp, Dept Med Pharmacol, Montpellier, France
[3] Lapeyronie Hosp, Dept Nephrol, Montpellier, France
[4] Caremeau Hosp, Dept Internal Med, Pneumol Dept A, Nimes, France
[5] Univ Paris 05, Cochin Hosp, Dept Internal Med & Infect Dis, Paris, France
[6] Univ Paris 05, Cochin Hosp, Pharmacovigilance Ctr, Paris, France
关键词
tenofovir; tubular injury; nephropathy; HIV; Fanconi syndrome;
D O I
10.1097/00126334-200403010-00007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We describe 7 cases of renal tubular injury in HIV-infected patients receiving an antiretroviral regimen containing tenofovir. Our patients (5 women and 2 men) developed renal tubular dysfunction, with hypophosphatemia, normoglycemic glycosuria, proteinuria, and decrease of creatinine clearance. The first biologic signs of renal toxicity were observed after duration of tenofovir treatment from 5 weeks to 16 months, and they resolved less than 4 months after discontinuation of tenofovir. Six patients had a low body weight (<60 kg). Five patients received low doses of ritonavir, and I received didanosine. In 5 patients, the signs resolved with the discontinuation of only the tenofovir. A renal biopsy performed in 1 patient was consistent with tubulointerstitial injury. Proximal tubulopathy appears to be a rare adverse effect of long-term tenofovir therapy. In patients with low weight or mild preexisting renal impairment, regular monitoring of tubulopathy markers could lead to early detection of this dysfunction.
引用
收藏
页码:269 / 273
页数:5
相关论文
共 22 条
[1]   Tenofovir: A nucleotide analog for the management of human immunodeficiency virus infection [J].
Antoniou, T ;
Park-Wyllie, LY ;
Tseng, AL .
PHARMACOTHERAPY, 2003, 23 (01) :29-43
[2]   Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults [J].
Barditch-Crovo, P ;
Deeks, SG ;
Collier, A ;
Safrin, S ;
Coakley, DF ;
Miller, M ;
Kearney, BP ;
Coleman, RL ;
Lamy, PD ;
Kahn, JO ;
McGowan, I ;
Lietman, PS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2733-2739
[3]   Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors [J].
Birkus, G ;
Hitchcock, MJM ;
Cihlar, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :716-723
[4]   Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors [J].
Cihlar, T ;
Birkus, G ;
Greenwalt, DE ;
Hitchcock, MJM .
ANTIVIRAL RESEARCH, 2002, 54 (01) :37-45
[5]   Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs [J].
Cihlar, T ;
Ho, ES ;
Lin, DC ;
Mulato, AS .
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2001, 20 (4-7) :641-648
[6]   Rapid communication: Acute renal failure associated with tenofovir: Evidence of drug-induced nephrotoxicity [J].
Coca, S ;
Perazella, MA .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2002, 324 (06) :342-344
[7]   Renal lesions in HIV-1-positive patient treated with tenofovir [J].
Créput, C ;
Gonzalez-Canali, G ;
Hill, G ;
Piketty, C ;
Kazatchkine, M ;
Nochy, D .
AIDS, 2003, 17 (06) :935-937
[8]  
CROWTHER MA, 1993, AIDS, V7, P131, DOI 10.1097/00002030-199301000-00025
[9]   Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir [J].
Cundy, KC .
CLINICAL PHARMACOKINETICS, 1999, 36 (02) :127-143
[10]  
Deray G, 1998, PRESSE MED, V27, P1801